RAPT Therapeutics, Inc. (RAPT) Equity Average (2020 - 2024)
RAPT Therapeutics' Equity Average history spans 5 years, with the latest figure at $102.4 million for Q3 2024.
- For Q3 2024, Equity Average fell 45.04% year-over-year to $102.4 million; the TTM value through Sep 2024 reached $102.4 million, down 45.04%, while the annual FY2023 figure was $196.1 million, 9.12% down from the prior year.
- Equity Average for Q3 2024 was $102.4 million at RAPT Therapeutics, down from $120.0 million in the prior quarter.
- Across five years, Equity Average topped out at $232.8 million in Q1 2023 and bottomed at $97.9 million in Q1 2021.
- The 5-year median for Equity Average is $168.5 million (2022), against an average of $162.9 million.
- The largest annual shift saw Equity Average soared 81.24% in 2021 before it tumbled 45.04% in 2024.
- A 5-year view of Equity Average shows it stood at $107.1 million in 2020, then skyrocketed by 81.24% to $194.1 million in 2021, then increased by 11.9% to $217.2 million in 2022, then decreased by 26.39% to $159.9 million in 2023, then crashed by 35.99% to $102.4 million in 2024.
- Per Business Quant, the three most recent readings for RAPT's Equity Average are $102.4 million (Q3 2024), $120.0 million (Q2 2024), and $138.9 million (Q1 2024).